Latest news with #46thAnnualGlobalHealthcareConference
Yahoo
03-07-2025
- Business
- Yahoo
Pacific Biosciences Targets Profitability by 2027 With Record Consumables Revenue
Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) delivered a presentation at the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 11. The company discussed its financial performance, highlighting both market limitations and growth prospects, and emphasized the promise of its long-read sequencing technology. Financially speaking, Pacific Biosciences of California (NASDAQ:PACB) reported that its consumable revenue in Q1 2025 reached a record $20.1 million, a 26% increase from the previous year. Additionally, by improving its gross margin, cutting operational costs, and increasing top-line growth, the company targets profitability by 2027. Pacific Biosciences of California (NASDAQ:PACB) is a biotech company that focuses on advanced genomic technologies, such as whole-genome sequencing, target sequencing, RNA sequencing, and epigenetics. By using its PacBio Sequel System, the company also developed a novel enrichment method for targeted SMRT sequencing. This greatly improves sequencing efficiency by using the CRISPR-Cas9 system to do away with the necessity for PCR amplification. While we acknowledge the potential of PACB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
17-06-2025
- Business
- Business Insider
RAPT Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a.m. ET UBS Spring Biotech Conference – Investor one-on-one meetings on Tuesday, June 24, 2025 To access the live webcast or subsequent archived recording of the Goldman Sachs fireside chat, please visit the RAPT Therapeutics website at About RAPT Therapeutics, Inc. RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
Yahoo
16-06-2025
- Business
- Yahoo
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing the imminent loss of exclusivity for its main medicine, Jakafi. In Q1 2025, Jakafi grew 24% year-over-year. According to management, three factors contributed to this growth. 10% came from demand, 7% from net pricing, and 7% from less destocking this year than in the same quarter last year. Looking ahead, Incyte Corporation (NASDAQ:INCY) anticipates that demand will be the only factor driving growth for the remainder of the year. To broaden its portfolio beyond Jakafi, however, the company intends to introduce four new products or indications in 2025, with the goal of generating an extra $1 billion in revenue by 2029. Incyte Corporation (NASDAQ:INCY), an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-06-2025
- Business
- Yahoo
Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
Sanofi (NASDAQ:SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (NASDAQ:SNY) on June 12, setting a price target of €118.00. The rating followed the company's presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, highlighting various growth drivers within Specialty Care that bring an optimistic light to its operations. Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry. Brian Foard, Head of Specialty Care at Sanofi (NASDAQ:SNY), stated that the product dupilumab is expected to undergo double-digit CAGR growth between 2023 and 2030, delivering an estimated EUR 22 billion by the end of the forecast period. He said that Sanofi's (NASDAQ:SNY) recently launched assets, such as ALTUVIIIO and Qfitlia, further add to this positive outlook. This also includes SARCLISA, the first FDA-approved treatment for adults with newly diagnosed multiple myeloma, which is continuing to expand its indications from both oncology and multiple myeloma perspectives. The company thus presented a growth story at the conference, including in neurology, where it anticipates a reentry into the MS space through the upcoming launch of tolebrutinib. Sanofi (NASDAQ:SNY) ranks 11th on our list of the best drug stocks to buy according to hedge funds. It researches, produces, and distributes pharmaceutical products. The company's operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments. While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Wire
12-06-2025
- Business
- Business Wire
U.S. Physical Therapy Presented at Investor Conferences
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that Chris Reading, Chief Executive Officer, presented at the Goldman Sachs 46 th Annual Global Healthcare Conference on June 10, 2025, and Carey Hendrickson, Chief Financial Officer, presented at the 15th Annual East Coast IDEAS Conference on June 11, 2025. The presentations provided an overview of the Company. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 775 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release.
